Ezra Cohen to Salvage Therapy
This is a "connection" page, showing publications Ezra Cohen has written about Salvage Therapy.
Connection Strength
0.187
-
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Sep; 17(9):1272-82.
Score: 0.126
-
Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005 Dec 01; 11(23):8418-24.
Score: 0.060